Nubain
Phase 3Small molecule
Nubain is one of 13 small molecule programs targeting Acute Chest Syndrome. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Acute Chest Syndrome
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Actemra
RochePhase 3
Decadron
AAspen Global Incorporated
Phase 3
MS Contin
HHikma Pharmaceuticals LLC
Phase 3
Inomax
MMallinckrodt
Phase 3
Defitelio
Jazz PharmaceuticalsPhase 2
Unfractionated Heparin
GSKPhase 2
Prophylactic Anticoagulation
AAssistance Publique - Hôpitaux de Paris
Phase 3
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nubain. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CChildren's Healthcare of Atlanta